Balykina Y.E., Kolbin A.S., Kurylev A.A., Pavlysh A.V., Proskurin M.A. 5044

Pharmacoeconomic evaluation of medicinal products used as first-line targeted therapy of metastatic kidney cancer

Abstract: A pharmacoeconomic evaluation of sunitinib as the firstline metastatic renal-cell carcinoma targeted agent in the Russian healthcare settings was performed in comparison with sorafenib and bevacizumab + interferon. A pharmacoeconomic Markov model was created and used to assess the costs and effectiveness (including mean overall survival in months) of each therapeutic regimen. The evaluation presented also includes a probabilistic multivariate sensitivity analysis. The results show that sunitinibbased treatment is dominant over sorafenib and bevacizumab + interferon, which makes it the most costeffectiveness treatment option.

Скорее всего ваш браузер не поддерживает PDF и Adobe Reader, нажмите здесь, чтобы просмотреть PDF